Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 13:16:11795735241260563.
doi: 10.1177/11795735241260563. eCollection 2024.

Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments

Erwan Muros-Le Rouzic  1 , Yanic Heer  2 , Sean Yiu  3 , Viola Tozzi  2 , Stefan Braune  4 , Philip van Hövell  2 , Arnfin Bergmann  4 , Corrado Bernasconi  1 , Fabian Model  1 , Licinio Craveiro  1 ; NTD study group
Affiliations

Five-year efficacy outcomes of ocrelizumab in relapsing multiple sclerosis: A propensity-matched comparison of the OPERA studies with other disease-modifying therapies in real-world lines of treatments

Erwan Muros-Le Rouzic et al. J Cent Nerv Syst Dis. .

Abstract

Background: Clinical trials comparing the efficacy of ocrelizumab (OCR) with other disease-modifying therapies (DMTs) other than interferon (IFN) β-1a in relapsing multiple sclerosis (RMS) are lacking.

Objectives: To compare the treatment effect of OCR vs six DMTs' (IFN β-1a, glatiramer acetate, fingolimod, dimethyl fumarate, teriflunomide, natalizumab) treatment pathways used in clinical practice by combining clinical trial and real-world data.

Methods: Patient-level data from OPERA trials and open-label extension phase, and from the German NeuroTransData (NTD) MS registry, were used to build 1:1 propensity score-matched (PSM) cohorts controlling for seven baseline covariates, including brain imaging activity. Efficacy outcomes were time to first relapse and time to 24-week confirmed disability progression over 5.5 years of follow-up. Intention-to-treat analysis using all outcome data irrespective of treatment switch was applied.

Results: The analyses included 611 OPERA patients and 7141 NTD patients. We built 12 paired-matched cohorts (six for each outcome, two for each DMT) to compare efficacy of OCR in OPERA with each DMT treatment pathway in NTD. Post-matching, baseline covariates and PS were well balanced (standardized mean difference <.2 for all cohorts). Over 5.5 years, patients treated with OCR showed a statistically significant reduction in the risk of relapse (hazard ratios [HRs] .30 to .54) and disability progression (HRs .51 to .67) compared with all index therapies and their treatment switching pathways in NTD. Treatment switch and/or discontinuation occurred frequently in NTD cohorts.

Conclusion: OCR demonstrates superiority in controlling relapses and disability progression in RMS compared with real-world treatment pathways over a 5.5-year period. These analyses suggest that high-efficacy DMTs and high treatment persistence are critical to achieve greatest clinical benefit in RMS.

Registration: OPERA I (NCT01247324), OPERA II (NCT01412333).

Keywords: Multiple sclerosis; comparative effectiveness research; ocrelizumab; real-world data; treatment pathways.

PubMed Disclaimer

Conflict of interest statement

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: F. Hoffmann-La Roche Ltd., Basel, Switzerland, provided financial support for the study and publication of this manuscript. Writing and editorial support was provided by Articulate Science, UK. E Muros-Le Rouzic is an employee of and shareholder in F. Hoffmann-La Roche Ltd. Y Heer was an employee of PricewaterhouseCoopers and contracted to perform statistical projects for NeuroTransData at the time of this analysis. S Yiu is an employee of Roche Products Ltd. V Tozzi is an employee of PricewaterhouseCoopers and contracted to perform statistical projects for NeuroTransData at the time of this analysis. S Braune has received honoraria from Kassenärztliche Vereinigung Bayerns and health maintenance organizations for patient care; and from Biogen, Merck, NeuroTransData, Novartis, and Roche for consulting, project management, clinical studies, and lectures; he also received honoraria and expense compensation as a board member of NeuroTransData. P van Hövell was an employee of PricewaterhouseCoopers and contracted to perform statistical projects for NeuroTransData at the time of this analysis. A Bergmann has received consultancy fees from advisory board, speaker, and other activities for NeuroTransData; project management and clinical studies for and travel expenses from Novartis and Servier. C Bernasconi is a consultant for F. Hoffmann-La Roche Ltd. F Model was an employee of and shareholder in F. Hoffmann-La Roche Ltd. at the time of this analysis and is now an employee of Denali Therapeutics. L Craveiro is an employee of and shareholder in F. Hoffmann-La Roche Ltd.

Figures

Figure 1.
Figure 1.
Love plots for absolute standardized differences after PSM for matching factors defined for relapse and 24W-CDP outcomes. 24W-CDP, 24-week confirmed disability progression; DMF, dimethyl fumarate; EDSS, Expanded Disability Status Scale; FTY, fingolimod; GA, glatiramer acetate; Gd+, gadolinium-enhancing; IFN β-1a, interferon β-1a; NTD, NeuroTransData registry; NTZ, natalizumab; OCR, ocrelizumab; PSM, propensity score-matched; TERI, teriflunomide.
Figure 2.
Figure 2.
Time to first relapse in patients receiving OCR in OPERA vs patients receiving each index therapy in the NTD-matched cohorts over 288 weeks. CI, confidence interval; DMF, dimethyl fumarate; FTY, fingolimod; GA, glatiramer acetate; HR, hazard ratio; IFN β-1a, interferon β-1a; NTD, NeuroTransData registry; NTZ, natalizumab; OCR, ocrelizumab; TERI, teriflunomide.
Figure 3.
Figure 3.
Time to discontinuation of each index therapy in the NTD-matched cohorts for time to first relapse outcome over 288 weeks. DMF, dimethyl fumarate; FTY, fingolimod; GA, glatiramer acetate; IFN β-1a, interferon β-1a; NTD, NeuroTransData registry; NTZ, natalizumab; TERI, teriflunomide.
Figure 4.
Figure 4.
Time to 24W-CDP relapse in patients receiving OCR in OPERA vs patients receiving each index therapy in the NTD-matched cohorts over 288 weeks. 24W-CDP, 24-week confirmed disability progression; CI, confidence interval; DMF, dimethyl fumarate; FTY, fingolimod; GA, glatiramer acetate; HR, hazard ratio; IFN β-1a, interferon β-1a; NTD, NeuroTransData registry; NTZ, natalizumab; OCR, ocrelizumab; TERI, teriflunomide.
Figure 5.
Figure 5.
Time to discontinuation of each index therapy in the NTD-matched cohorts for time to 24W-CDP outcome over 288 weeks. 24W-CDP, 24-week confirmed disability progression; DMF, dimethyl fumarate; FTY, fingolimod; GA, glatiramer acetate; IFN β-1a, interferon β-1a; NTD, NeuroTransData registry; NTZ, natalizumab; TERI, teriflunomide.
See this image and copyright information in PMC

References

    1. European Medicines Agency . Ocrevus [Summary of product characteristics], https://www.ema.europa.eu/en/documents/product-information/ocrevus-epar-.... (2021, accessed January 18, 2021). [Not Available in CrossRef].
    1. Genentech . Ocrevus (Ocrelizumab) [Full prescribing information], https://www.gene.com/download/pdf/ocrevus_prescribing.pdf. (2020, accessed January 20, 2020).
    1. Hauser SL Bar-Or A Comi G, et al. OPERA I and OPERA II Clinical Investigators. . Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221-234. - PubMed
    1. Asha MZI, Al-Asaad Y, Khalil SFH. The comparative efficacy and safety of anti-CD20 monoclonal antibodies for relapsing-remitting multiple sclerosis: a network meta-analysis. IBRO Neurosci Rep. 2021;11:103-111 - PMC - PubMed
    1. Bose D, Ravi R, Maurya M, Pushparajan L, Konwar M. Impact of disease-modifying therapies on MRI outcomes in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. Mult Scler Relat Disord. 2022;61:103760. - PubMed

Associated data

LinkOut - more resources